Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication alleviates symptoms of major depression in as little as a few hours.

Tiara Gray was diagnosed with 3 mental conditions, including bordeline personality disorder. Yet the Navy kept her in a high-pressure job.

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Cybin (TSE:CYBN) has released an update. Cybin has launched a pivotal Phase 3 program named PARADIGM to evaluate CYB003 as a treatment for Major Depressive Disorder, involving multiple studies across ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...